Guideline-Endorsed Answers to Key Questions in Nontuberculous Mycobacterial Lung Disease Management

Download All
Get up to date with the experts on practice guidelines and how to provide individualized and comprehensive treatment plans in partnership with your patients with NTM-LD. Download slides, read ClinicalThought faculty commentaries, or explore the on-demand multimedia module from this engaging symposium.
person default
David E. Griffith, MD
Princy N. Kumar, MD, FIDSA, MACP
person default
Anonymous Patient

ClinicalThought

It took 15 years and several doctors to reach a diagnosis of NTM lung disease, but today I am living without the assistance of medications. 

person default Anonymous Patient Released: September 30, 2021

One of the most frustrating and misunderstood aspects of NTM disease management is the lack of clear correlation between in vitro activity of the drug and the outcome of in vivo treatment.

person default David E. Griffith, MD Released: December 1, 2021

Attention to safety concerns for patients receiving treatment for NTM lung disease is paramount. Here are some of the steps I take while following patients as they undergo treatment.

Princy N. Kumar, MD, FIDSA, MACP Released: November 30, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Insmed Incorporated

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue